Heart risk from leukemia drugs under the microscope

NCT ID NCT05724121

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 11 times

Summary

This study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand and identify heart problems early in patients on these treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BTK inhibitors or venetoclax
What this could lead to
If successful, this study could help doctors better monitor and prevent heart rhythm problems in people taking BTK inhibitors for blood cancers.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly benefit participants. It may not find clear links or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC ARRHYTHMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.